Clinical Trials Directory

Trials / Completed

CompletedNCT00465621

Dose Response Study of AL-37807 Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
150 (estimated)
Sponsor
Alcon Research · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of thie study is to compare the safety and IOP-lowering efficacy of AL-37807 Ophthalmic Solution 0.05%, 0.1% and 0.2% dosed QD AM to Xalatan dosed QD PM and Vehicle in patients with open-angle glaucoma or ocular hypertension

Conditions

Interventions

TypeNameDescription
DRUGXalatan

Timeline

Start date
2007-03-01
Primary completion
2007-07-01
First posted
2007-04-25
Last updated
2008-07-29

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00465621. Inclusion in this directory is not an endorsement.